Evaluation of the efficacy and tolerance of a cosmetic mask containing 89% of vichy volcanic mineralizing water and hyaluronic acid after facial laser procedures.

M89 mask erythema facial laser quality of life skin skin hydration

Journal

Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 17 12 2020
accepted: 29 12 2020
pubmed: 5 2 2021
medline: 20 8 2021
entrez: 4 2 2021
Statut: ppublish

Résumé

M89 M (Mineral 89 mask, Laboratoires Vichy, France), containing 89% Vichy volcanic mineralizing water and hyaluronic acid, aims to strengthen and repair skin barrier. To assess the efficacy, tolerance, patient satisfaction, and quality of life (QOL) using M89 M after laser procedures (LP). M89 M was applied immediately post-LP for 10 minutes, then daily for 5 days and 2-3 times a week, up to 28 days on the faces of 51 women. Evaluations were performed immediately post-LP, immediately after M89 M application at D0, D1, D5, and D28, and included criteria such as erythema and skin dryness. Subjects scored burning and warm sensations, itching, skin tightness, and stinging. Skin hydration using a Corneometer, skin barrier integrity using a Tewameter, and erythema using a Chromameter were assessed. Local tolerance and adverse events were recorded. After 28 days, subjects answered a questionnaire regarding the M89 M subjective cosmetic properties and QOL. All subjects were in their mid-forties with a phototype of II, III, or IV. M89 M significantly (P < .001) reduced the immediate cutaneous discomfort sensation and laser procedure-related symptoms (burning, warmth sensation, itching/stinging, skin tightness). Skin hydration, and erythema, assessed using instrumental measures, were also significantly improved immediately after mask application (P ≤ .01). Subjects highly appreciated M89 M and their QOL improved after 28 days of use. Local tolerance was good to excellent in both studies. M89 M is effective and safe immediately after esthetic procedures such as ablative and nonablative lasers and also improves the subject's QOL.

Sections du résumé

BACKGROUND BACKGROUND
M89 M (Mineral 89 mask, Laboratoires Vichy, France), containing 89% Vichy volcanic mineralizing water and hyaluronic acid, aims to strengthen and repair skin barrier.
AIMS OBJECTIVE
To assess the efficacy, tolerance, patient satisfaction, and quality of life (QOL) using M89 M after laser procedures (LP).
METHODS METHODS
M89 M was applied immediately post-LP for 10 minutes, then daily for 5 days and 2-3 times a week, up to 28 days on the faces of 51 women. Evaluations were performed immediately post-LP, immediately after M89 M application at D0, D1, D5, and D28, and included criteria such as erythema and skin dryness. Subjects scored burning and warm sensations, itching, skin tightness, and stinging. Skin hydration using a Corneometer, skin barrier integrity using a Tewameter, and erythema using a Chromameter were assessed. Local tolerance and adverse events were recorded. After 28 days, subjects answered a questionnaire regarding the M89 M subjective cosmetic properties and QOL.
RESULTS RESULTS
All subjects were in their mid-forties with a phototype of II, III, or IV. M89 M significantly (P < .001) reduced the immediate cutaneous discomfort sensation and laser procedure-related symptoms (burning, warmth sensation, itching/stinging, skin tightness). Skin hydration, and erythema, assessed using instrumental measures, were also significantly improved immediately after mask application (P ≤ .01). Subjects highly appreciated M89 M and their QOL improved after 28 days of use. Local tolerance was good to excellent in both studies.
CONCLUSION CONCLUSIONS
M89 M is effective and safe immediately after esthetic procedures such as ablative and nonablative lasers and also improves the subject's QOL.

Identifiants

pubmed: 33538111
doi: 10.1111/jocd.13972
pmc: PMC8451765
doi:

Substances chimiques

Water 059QF0KO0R
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2860-2866

Subventions

Organisme : Laboratoires Vichy

Informations de copyright

© 2021 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.

Références

J Dermatol Sci. 2017 Mar;85(3):152-161
pubmed: 27720464
J Cosmet Laser Ther. 2018 Nov - Dec;20(7-8):424-435
pubmed: 30395754
J Clin Aesthet Dermatol. 2012 Jun;5(6):45-53
pubmed: 22768357
Ann Dermatol Venereol. 2010 Apr;137 Suppl 1:S3-8
pubmed: 20435253
J Cosmet Dermatol. 2020 Mar;19(3):682-688
pubmed: 31793738
Laser Ther. 2011;20(3):181-8
pubmed: 24155527
Mech Ageing Dev. 2018 Jun;172:123-130
pubmed: 29287765
J Plast Surg Hand Surg. 2013 Apr;47(2):89-92
pubmed: 23356944
Lasers Surg Med. 2005 Jan;36(1):47-51
pubmed: 15662626
Clin Cosmet Investig Dermatol. 2020 Oct 05;13:751-758
pubmed: 33116738
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Pharm Pharm Sci. 2015;18(1):53-60
pubmed: 25877441
Dermatol Surg. 2004 Aug;30(8):1073-6
pubmed: 15274695
J Clin Aesthet Dermatol. 2017 Jun;10(6):51-67
pubmed: 28979657
J Cosmet Dermatol. 2021 Sep;20(9):2860-2866
pubmed: 33538111
Ann Intern Med. 2013 Jun 4;158(11):781-90
pubmed: 23732711

Auteurs

Paulo Torreao (P)

PRA Health Sciences, Mannheim, Germany.

Edmond Phua (E)

Boris Valerie Medical Aesthetics Clinic, Singapore, Singapore.

Raphael Clark (R)

Centre International de Développement Pharmaceutique (Research Institute), Rio de Janeiro, Brazil.

Erika Fernandes (E)

Centre International de Développement Pharmaceutique (Research Institute), Rio de Janeiro, Brazil.

Thais Pontes (T)

Centre International de Développement Pharmaceutique (Research Institute), Rio de Janeiro, Brazil.

Ana P Fonseca (AP)

Centre International de Développement Pharmaceutique (Research Institute), Rio de Janeiro, Brazil.

Nadia Singh (N)

Centre International de Développement Pharmaceutique (Research Institute), Singapore, Singapore.

Bandana Seesurn (B)

Centre International de Développement Pharmaceutique (Research Institute), Singapore, Singapore.

Marion Nielsen (M)

Laboratoires Vichy International, Levallois-Perret, France.

Audrey Valois (A)

Laboratoires Vichy International, Levallois-Perret, France.

Delphine Kerob (D)

Laboratoires Vichy International, Levallois-Perret, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH